3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Ovarian Neoplasms
9
Fallopian Tube Neoplasms
8
Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Recurrence
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Interventions
enzalutamide
8
Abiraterone Acetate
4
rucaparib
2
Prednisone
2
Docetaxel
2
sabizabulin
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration Resistant Prostate Cancer
×
rucaparib
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA
NCT04179396
2023-06-29
RAMP
pharmaand GmbH
Phase 1
Completed
8 enrolled
8 charts